Tandem Diabetes Care Executive Compensation Revealed

TL;DR

Tandem Diabetes Care's proxy statement is out, showing exec comp details for 2023. Check it for stock awards & equity value changes.

AI Summary

Tandem Diabetes Care Inc. filed its DEF 14A on April 9, 2024, detailing executive compensation for the fiscal year ending December 31, 2023. The filing includes information on stock awards granted, the year-end value of unvested equity awards, and changes in the value of equity awards for both PEO and Non-PEO members. Specific dollar amounts and the exact number of awards are detailed within the proxy statement.

Why It Matters

This filing provides insight into how Tandem Diabetes Care compensates its top executives, which can influence investor perception and employee morale.

Risk Assessment

Risk Level: medium — DEF 14A filings are routine but can reveal significant information about executive compensation and corporate governance that may impact stock price.

Key Numbers

• 2023 — Fiscal Year (Period covered by the executive compensation details)
• 1231 — Fiscal Year End (Specific date for the end of the reporting fiscal year)

Key Players & Entities

• Tandem Diabetes Care Inc. (company) — Filer of the DEF 14A
• 2023-12-31 (date) — Fiscal year end for compensation details
• April 9, 2024 (date) — Filing date of the DEF 14A

FAQ

From the Filing

0001438133-24-000076.txt : 20240409 0001438133-24-000076.hdr.sgml : 20240409 20240409165437 ACCESSION NUMBER: 0001438133-24-000076 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20240409 FILED AS OF DATE: 20240409 DATE AS OF CHANGE: 20240409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 24833336 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 DEF 14A 1 tndm-20240409.htm DEF 14A tndm-20240409 0001438133 DEF 14A FALSE 0001438133 2023-01-01 2023-12-31 iso4217:USD 0001438133 2022-01-01 2022-12-31 0001438133 2021-01-01 2021-12-31 0001438133 tndm:StockAwardsGrantedInYearMember ecd:PeoMember 2023-01-01 2023-12-31 0001438133 tndm:YearEndValueOfUnvestedEquityAwardsGrantedInYearMember ecd:PeoMember 2023-01-01 2023-12-31 0001438133 tndm:ChangeInValueOfUnvestedEquityAwardsGrantedInPriorYearsMember ecd:PeoMember 2023-01-01 2023-12-31 0001438133 tndm:ChangeInValueOfEquityAwardsGrantedInPriorYearsWhichVestedInYearMember ecd:PeoMember 2023-01-01 2023-12-31 0001438133 ecd:NonPeoNeoMember tndm:StockAwardsGrantedInYearMember 2023-01-01 2023-12-31 0001438133 tndm:YearEndValueOfUnvestedEquityAwardsGrantedInYearMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001438133 ecd:NonPeoNeoMember tndm:ChangeInValueOfUnvestedEquityAwardsGrantedInPriorYearsMember 2023-01-01 2023-12-31 0001438133 tndm:ChangeInValueOfEquityAwardsGrantedInPriorYearsWhichVestedInYearMember ecd:NonPeoNeoMember 2023-01-01 2023-12-31 0001438133 2 2023-01-01 2023-12-31 0001438133 1 2023-01-01 2023-12-31 0001438133 3 2023-01-01 2023-12-31 0001438133 4 2023-01-01 2023-12-31   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934   Filed by the Registrant x Filed by a Party other than the Registrant ☐  Check the appropriate box:   ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ☐  Definitive Additional Materials ☐  Soliciting Material under 240.14a-12 Tandem Diabetes Care, Inc .   (Name of Registrant as Specified In Its Charter)   (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed in table in exhibit required by Item 25(b) per Exchange Act Rule 14a-6(i)(1) and 0-11.     Notice of Annual Meeting of Stockholders DATE May 22, 2024 TIME 3:00 p.m. Pacific Time MEETING WEB ADDRESS www.virtualshareholdermeeting.com/TNDM2024 Dear Stockholders: You are cordially invited to attend the 2024 Annual Meeting of Stockholders of Tandem Diabetes Care, Inc., or the Annual Meeting, which will be held on Wednesday, May 22, 2024 at 3:00 p.m., Pacific Time. The Annual Meeting will be held virtually by live internet webcast at www.virtualshareholdermeeting.com/TNDM2024. We are holding the Annual Meeting for the following purposes, as more fully described in the accompanying Proxy Statement: 1. To elect nine directors for a one-year term expiring at the 2025 annual meeting of stockholders. 2. To approve the Company’s 2013 Employee Stock Purchase Plan, as Amended, to Increase the Number of Shares Authorized for Issuance Under the Plan. 3. To approve the Company’s 2023 Long-Term Incentive P